Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mitoxantrone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    97 result(s) found for: Mitoxantrone. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2007-001962-34 Sponsor Protocol Number: inims-2 Start Date*: 2007-12-12
    Sponsor Name:University Medical Center Hamburg Eppendorf
    Full Title: Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie
    Medical condition: secondary progressive multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001671-38 Sponsor Protocol Number: C0328T07 Start Date*: 2007-05-23
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Canc...
    Medical condition: Metastatic Hormone-Refractory Prostate Cancer (HRPC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-018015-11 Sponsor Protocol Number: IMCLCP15-0805 Start Date*: 2010-10-20
    Sponsor Name:ImClone LLC
    Full Title: A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CR...
    Medical condition: Metastatic Castration-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-001569-33 Sponsor Protocol Number: LLC-R-FCM-1 Start Date*: 2005-09-23
    Sponsor Name:Dept. Hematology, Hospital Clinic
    Full Title: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamie...
    Medical condition: Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004903-39 Sponsor Protocol Number: WCNNMBJR001 Start Date*: 2005-07-26
    Sponsor Name:The Walton Centre for Neurology and Neurosurgery
    Full Title: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.
    Medical condition: Early, active relapsing remitting Multiple Sclerosis (RRMS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001026-89 Sponsor Protocol Number: 25874 Start Date*: 2005-07-14
    Sponsor Name:Serono GmbH
    Full Title: Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple scle...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with relapses
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028245 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004355-30 Sponsor Protocol Number: 20070611 Start Date*: 2009-01-05
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer
    Medical condition: Previously Treated Castrate Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) FR (Completed) NL (Completed) FI (Completed) SE (Completed) BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001588-22 Sponsor Protocol Number: AML003 Start Date*: 2019-07-04
    Sponsor Name:Rafael Pharmaceuticals, Inc.
    Full Title: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mi...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001286-17 Sponsor Protocol Number: REMIT0401 Start Date*: 2006-09-08
    Sponsor Name:Fundación Española de Esclerosis Múltiple (FEDEM)
    Full Title: Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresi...
    Medical condition: Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002986-30 Sponsor Protocol Number: CLBH589B2116 Start Date*: 2010-01-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia
    Medical condition: refractory or relapsed acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012337-29 Sponsor Protocol Number: IILFLE09 Start Date*: 2009-07-20
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma
    Medical condition: Elderly patients with advanced stage previously untreated follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001421-34 Sponsor Protocol Number: TPLL2 Start Date*: 2009-12-07
    Sponsor Name:University of Cologne, Sponsor-Quality Management
    Full Title: Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Le...
    Medical condition: Untreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003086-40 Sponsor Protocol Number: PIX001 Start Date*: 2008-04-08
    Sponsor Name:Fondation Charcot Stichting
    Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)
    Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010661-23 Sponsor Protocol Number: 2009-010661-23 Start Date*: 2009-07-30
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
    Full Title: MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition: subjects affected by secondary-progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006342-25 Sponsor Protocol Number: HM08 / 8625 Start Date*: 2009-02-09
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or withou...
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003025-28 Sponsor Protocol Number: TUD-RELAX1-070 Start Date*: Information not available in EudraCT
    Sponsor Name:Technische Universität Dresden
    Full Title: Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax
    Medical condition: Patients 18-75 years with acute myeloid leukaemia (AML) at first or second relapse after intensive chemotherapy including allogeneic stem cell transplantation or primary refractory to standard indu...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000256-26 Sponsor Protocol Number: Start Date*: 2009-02-16
    Sponsor Name:Queen Mary, University of London
    Full Title: An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neu...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003103-12 Sponsor Protocol Number: AML-CG2008 Start Date*: 2009-03-10
    Sponsor Name:Hospital of the University of Munich
    Full Title: A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy ...
    Medical condition: Adult patients (≥18 years) with newly-diagnosed acute myeloid leukemia (AML) - except acute promyelocytic leukemia (APL) and t(15;17)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001426-99 Sponsor Protocol Number: XL184–306 Start Date*: 2012-07-11
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer
    Medical condition: castration-resistant prostate cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004890-28 Sponsor Protocol Number: AC220-007 Start Date*: 2014-06-18
    Sponsor Name:Daiichi Sankyo Inc
    Full Title: A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-li...
    Medical condition: Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Ongoing) IT (Completed) NL (Completed) ES (Ongoing) BE (Completed) HU (Completed) CZ (Completed) HR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:38:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA